Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287605 | 0.84 | CA12 (0.35) | MAPT | |
| SCHEMBL2285003 | 0.77 | MAPT (0.39) | POLBL3MBTL1MAPTNPSR1ALOX5 | |
| SCHEMBL2288733 | 0.77 | TUBB1 (0.33) | L3MBTL1 | |
| SCHEMBL2290810 | 0.76 | TUBB1 (0.31) | — | |
| SCHEMBL2285273 | 0.76 | L3MBTL1 (0.35) | POLBL3MBTL1MAPTNPSR1ALOX5 | |
| SCHEMBL943918 | 0.76 | CA2 (0.41) | POLBL3MBTL1MAPTNPSR1ALOX5 | |
| SCHEMBL4032984 | 0.75 | — | — | |
| SCHEMBL2285493 | 0.74 | MAPT (0.32) | POLBL3MBTL1MAPTNPSR1 | |
| SCHEMBL1298973 | 0.74 | ALOX5 (0.50) | POLBL3MBTL1MAPTNPSR1ALOX5 | |
| SCHEMBL2286239 | 0.74 | POLB (0.34) | POLBL3MBTL1MAPTNPSR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929683-A | Pyridine derivatives as calcium-activated chloride channel modulators | 跨膜蛋白16A有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-7989394-B2 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | AAAS, AIPL1, ATXN2 | POLB 4882/4885L3MBTL1 1463/4885MAPT 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.